Article
Timing issues are important when treating invasive TCC
Articles in this month's Urology Times deal with an issue of "timing"when determining the treatment of invasive transitional cell carcinoma ofthe bladder.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
RX Review: Redefining treatment for LG-IR-NMIBC
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Understanding pediatric urologist burnout
Urologist finds Rezum AE rates in larger prostates “reassuring”
Men’s Health Awareness Month: A new era of patient engagement
The Logistical Challenges in ccRCC Treatment
Related Content
